This announcement is a separate document:
广东华商(长沙)律师事务所关于湖南方盛制药股份有限公司2022年股权激励计划部分限制性股票回购注销实施相关事项的法律意见书
Legal Opinion of Guangdong Huashang (Changsha) Law Firm on the Implementation of Partial Restricted Stock Buyback and Cancellation of Hunan Fangsheng Pharmaceutical Co., Ltd.'s 2022 Stock-Based Incentive Plan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.